Search

Your search keyword '"Inker, Lesley"' showing total 1,256 results
Start Over Author "Inker, Lesley"
1,256 results on '"Inker, Lesley"'

251. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.

Author

Inker, Lesley, Inker, Lesley, Grams, Morgan, Levey, Andrew, Coresh, Josef, Cirillo, Massimo, Collins, John, Gansevoort, Ron, Gutierrez, Orlando, Hamano, Takayuki, Heine, Gunnar, Ishikawa, Shizukiyo, Jee, Sun, Kronenberg, Florian, Landray, Martin, Miura, Katsuyuki, Nadkarni, Girish, Peralta, Carmen, Rothenbacher, Dietrich, Schaeffner, Elke, Sedaghat, Sanaz, Zhang, Luxia, van Zuilen, Arjan, Hallan, Stein, Kovesdy, Csaba, Woodward, Mark, Levin, Adeera, Shlipak, Michael, Inker, Lesley, Inker, Lesley, Grams, Morgan, Levey, Andrew, Coresh, Josef, Cirillo, Massimo, Collins, John, Gansevoort, Ron, Gutierrez, Orlando, Hamano, Takayuki, Heine, Gunnar, Ishikawa, Shizukiyo, Jee, Sun, Kronenberg, Florian, Landray, Martin, Miura, Katsuyuki, Nadkarni, Girish, Peralta, Carmen, Rothenbacher, Dietrich, Schaeffner, Elke, Sedaghat, Sanaz, Zhang, Luxia, van Zuilen, Arjan, Hallan, Stein, Kovesdy, Csaba, Woodward, Mark, Levin, Adeera, and Shlipak, Michael

Abstract

RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) is complicated by abnormalities that reflect disruption in filtration, tubular, and endocrine functions of the kidney. Our aim was to explore the relationship of specific laboratory result abnormalities and hypertension with the estimated glomerular filtration rate (eGFR) and albuminuria CKD staging framework. STUDY DESIGN: Cross-sectional individual participant-level analyses in a global consortium. SETTING & STUDY POPULATIONS: 17 CKD and 38 general population and high-risk cohorts. SELECTION CRITERIA FOR STUDIES: Cohorts in the CKD Prognosis Consortium with data for eGFR and albuminuria, as well as a measurement of hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, or calcium, or hypertension. DATA EXTRACTION: Data were obtained and analyzed between July 2015 and January 2018. ANALYTICAL APPROACH: We modeled the association of eGFR and albuminuria with hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, and calcium values using linear regression and with hypertension and categorical definitions of each abnormality using logistic regression. Results were pooled using random-effects meta-analyses. RESULTS: The CKD cohorts (n=254,666 participants) were 27% women and 10% black, with a mean age of 69 (SD, 12) years. The general population/high-risk cohorts (n=1,758,334) were 50% women and 2% black, with a mean age of 50 (16) years. There was a strong graded association between lower eGFR and all laboratory result abnormalities (ORs ranging from 3.27 [95% CI, 2.68-3.97] to 8.91 [95% CI, 7.22-10.99] comparing eGFRs of 15 to 29 with eGFRs of 45 to 59mL/min/1.73m2), whereas albuminuria had equivocal or weak associations with abnormalities (ORs ranging from 0.77 [95% CI, 0.60-0.99] to 1.92 [95% CI, 1.65-2.24] comparing urinary albumin-creatinine ratio > 300 vs < 30mg/g). LIMITATIONS: Variations in study era, health care delivery system, typical diet, and laboratory

Published
2019

252. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Author

Heerspink, Hiddo J L, primary, Stack, Austin G, additional, Terkeltaub, Robert, additional, Greene, Tom A, additional, Inker, Lesley A, additional, Bjursell, Magnus, additional, Perl, Shira, additional, Rikte, Tord, additional, Erlandsson, Fredrik, additional, and Perkovic, Vlado, additional

Published
2021
Full Text
View/download PDF

254. Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report from the NKF-ASN Task Force

Author

Delgado, Cynthia, primary, Baweja, Mukta, additional, Burrows, Nilka Ríos, additional, Crews, Deidra C., additional, Eneanya, Nwamaka D., additional, Gadegbeku, Crystal A., additional, Inker, Lesley A., additional, Mendu, Mallika L., additional, Miller, W. Greg, additional, Moxey-Mims, Marva M., additional, Roberts, Glenda V., additional, St. Peter, Wendy L., additional, Warfield, Curtis, additional, and Powe, Neil R., additional

Published
2021
Full Text
View/download PDF

256. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes.

Author

Grams, Morgan E., Brunskill, Nigel J., Ballew, Shoshana H., Sang, Yingying, Coresh, Josef, Matsushita, Kunihiro, Surapaneni, Aditya, Bell, Samira, Carrero, Juan J., Chodick, Gabriel, Evans, Marie, Heerspink, Hiddo J.L., Inker, Lesley A., Iseki, Kunitoshi, Kalra, Philip A., Kirchner, H. Lester, Lee, Brian J., Levin, Adeera, Major, Rupert W., and Medcalf, James

Subjects
CHRONIC kidney failure, GLOMERULAR filtration rate, RESEARCH, KIDNEYS, META-analysis, KIDNEY failure, RESEARCH methodology, DIABETES, EVALUATION research, COMPARATIVE studies, RESEARCH funding, ALBUMINURIA
Abstract

Objective: To predict adverse kidney outcomes for use in optimizing medical management and clinical trial design.Research Design and Methods: In this meta-analysis of individual participant data, 43 cohorts (N = 1,621,817) from research studies, electronic medical records, and clinical trials with global representation were separated into development and validation cohorts. Models were developed and validated within strata of diabetes mellitus (presence or absence) and estimated glomerular filtration rate (eGFR; ≥60 or <60 mL/min/1.73 m2) to predict a composite of ≥40% decline in eGFR or kidney failure (i.e., receipt of kidney replacement therapy) over 2-3 years.Results: There were 17,399 and 24,591 events in development and validation cohorts, respectively. Models predicting ≥40% eGFR decline or kidney failure incorporated age, sex, eGFR, albuminuria, systolic blood pressure, antihypertensive medication use, history of heart failure, coronary heart disease, atrial fibrillation, smoking status, and BMI, and, in those with diabetes, hemoglobin A1c, insulin use, and oral diabetes medication use. The median C-statistic was 0.774 (interquartile range [IQR] = 0.753, 0.782) in the diabetes and higher-eGFR validation cohorts; 0.769 (IQR = 0.758, 0.808) in the diabetes and lower-eGFR validation cohorts; 0.740 (IQR = 0.717, 0.763) in the no diabetes and higher-eGFR validation cohorts; and 0.750 (IQR = 0.731, 0.785) in the no diabetes and lower-eGFR validation cohorts. Incorporating the previous 2-year eGFR slope minimally improved model performance, and then only in the higher-eGFR cohorts.Conclusions: Novel prediction equations for a decline of ≥40% in eGFR can be applied successfully for use in the general population in persons with and without diabetes with higher or lower eGFR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

257. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

Author

Roth, Gregory A., Mensah, George A., Johnson, Catherine O., Addolorato, Giovanni, Ammirati, Enrico, Baddour, Larry M., Barengo, Noël C., Beaton, Andrea Z., Benjamin, Emelia J., Benziger, Catherine P., Bonny, Aimé, Brauer, Michael, Brodmann, Marianne, Cahill, Thomas J., Carapetis, Jonathan, Catapano, Alberico L., Chugh, Sumeet S., Cooper, Leslie T., Coresh, Josef, Criqui, Michael, DeCleene, Nicole, Eagle, Kim A., Emmons-Bell, Sophia, Feigin, Valery L., Fernández-Solà, Joaquim, Fowkes, Gerry, Gakidou, Emmanuela, Grundy, Scott M., He, Feng J., Howard, George, Hu, Frank, and Inker, Lesley

Subjects
global health, health policy, population health, cardiovascular diseases
Abstract

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.

Published
2020

258. Номенклатура функции и болезней почек: отчет о результатах согласительной конференции инициативы по улучшению глобальных исходов заболеваний почек (KDIGO)

Author

Levey, Andrew S., Eckardt, Kai Uwe, Dorman, Nijsje M., Christiansen, Stacy L., Hoorn, Ewout J., Ingelfinger, Julie R., Inker, Lesley A., Levin, Adeera, Mehrotra, Rajnish, Palevsky, Paul M., Perazella, Mark A., Tong, Allison, Allison, Susan J., Bockenhauer, Detlef, Briggs, Josephine P., Bromberg, Jonathan S., Davenport, Andrew, Feldman, Harold I., Fouque, Denis, Gansevoort, Ron T., Gill, John S., Greene, Eddie L., Hemmelgarn, Brenda R., Kretzler, Matthias, Lambie, Mark, Lane, Pascale H., Laycock, Joseph, Leventhal, Shari E., Mittelman, Michael, Morrissey, Patricia, Ostermann, Marlies, Rees, Lesley, Ronco, Pierre, Schaefer, Franz, St. Clair Russell, Jennifer, Vinck, Caroline, Walsh, Stephen B., Weiner, Daniel E., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Internal Medicine

Subjects
urogenital system
Abstract

The worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for more effective communication by stakeholders in the kidney health community. Despite this need for clarity, the nomenclature for describing kidney function and disease lacks uniformity. In June 2019, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Consensus Conference with the goal of standardizing and refining the nomenclature used in the English language to describe kidney function and disease, and of developing a glossary that could be used in scientific publications. Guiding principles of the conference were that the revised nomenclature should be patient-centered, precise, and consistent with nomenclature used in the KDIGO guidelines. Conference attendees reached general consensus on the following recommendations: (i) to use “kidney” rather than “renal” or “nephro-” when referring to kidney disease and kidney function; (ii) to use “kidney failure” with appropriate descriptions of presence or absence of symptoms, signs, and treatment, rather than “end-stage kidney disease”; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI), rather than alternative descriptions, to define and classify severity of AKD and AKI; (iv) to use the KDIGO definition and classification of chronic kidney disease (CKD) rather than alternative descriptions to define and classify severity of CKD; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate (GFR), rather than “abnormal” or “reduced” kidney function to describe alterations in kidney structure and function. A proposed 5-part glossary contains specific items for which there was general agreement. Conference attendees acknowledged limitations of the recommendations and glossary, but they considered standardization of scientific nomenclature to be essential for improving communication.

Published
2020

259. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race

Author

Inker, Lesley A., Eneanya, Nwamaka D., Coresh, Josef, Tighiouart, Hocine, Wang, Dan, Sang, Yingying, Crews, Deidra C., Doria, Alessandro, Estrella, Michelle M., Froissart, Marc, Grams, Morgan E., Greene, Tom, Grubb, Anders, Gudnason, Vilmundur, Gutierrez, Orlando M., Kalil, Roberto, Karger, Amy B., Mauer, Michael, Navis, Gerjan, Nelson, Robert G., Poggio, Emilio D., Rodby, Roger, Rossing, Peter, Rule, Andrew D., Selvin, Elizabeth, Seegmiller, Jesse C., Shlipak, Michael G., Torres, Vicente E., Yang, Wei, Ballew, Shoshana H., Couture, Sara J., Powe, Neil R., Levey, Andrew S., Inker, Lesley A., Eneanya, Nwamaka D., Coresh, Josef, Tighiouart, Hocine, Wang, Dan, Sang, Yingying, Crews, Deidra C., Doria, Alessandro, Estrella, Michelle M., Froissart, Marc, Grams, Morgan E., Greene, Tom, Grubb, Anders, Gudnason, Vilmundur, Gutierrez, Orlando M., Kalil, Roberto, Karger, Amy B., Mauer, Michael, Navis, Gerjan, Nelson, Robert G., Poggio, Emilio D., Rodby, Roger, Rossing, Peter, Rule, Andrew D., Selvin, Elizabeth, Seegmiller, Jesse C., Shlipak, Michael G., Torres, Vicente E., Yang, Wei, Ballew, Shoshana H., Couture, Sara J., Powe, Neil R., and Levey, Andrew S.

Abstract

New Equations for Estimating GFR without Race Equations for estimating GFR with serum creatinine overestimate measured GFR in Blacks. The authors report new equations, without race as an inflation factor, using cystatin C and creatinine that reduced errors in estimation between Black participants and non-Black participants.Background Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a social and not a biologic construct. Methods We developed new eGFR equations without race using data from two development data sets: 10 studies (8254 participants, 31.5% Black) for serum creatinine and 13 studies (5352 participants, 39.7% Black) for both serum creatinine and cystatin C. In a validation data set of 12 studies (4050 participants, 14.3% Black), we compared the accuracy of new eGFR equations to measured GFR. We projected the prevalence of chronic kidney disease (CKD) and GFR stages in a sample of U.S. adults, using current and new equations. Results In the validation data set, the current creatinine equation that uses age, sex, and race overestimated measured GFR in Blacks (median, 3.7 ml per minute per 1.73 m(2) of body-surface area; 95% confidence interval [CI], 1.8 to 5.4) and to a lesser degree in non-Blacks (median, 0.5 ml per minute per 1.73 m(2); 95% CI, 0.0 to 0.9). When the adjustment for Black race was omitted from the current eGFR equation, measured GFR in Blacks was underestimated (median, 7.1 ml per minute per 1.73 m(2); 95% CI, 5.9 to 8.8). A new equation using age and sex and omitting race underestimated measured GFR in Blacks (median, 3.6 ml per minute per 1.73 m(2); 95% CI, 1.8 to 5.5) and overestimated measured GFR in non-Blacks (median, 3.9 ml per minute per 1.73 m(2); 95% CI, 3.4 to 4.4). For all equations, 85% or more of the eGFRs for Blacks and non-Blacks were within 30% of measured GFR. New crea

Published
2021

261. Contributors

Author

Adler, Sharon, primary, Adrogué, Horacio J., additional, Allon, Michael, additional, Arif-Tiwari, Hina, additional, Arroyo, Vincente, additional, Avery, Robin K., additional, Avila-Casado, Carmen, additional, Barratt, Jonathan, additional, Berns, Jeffrey S., additional, Bomback, Andrew S., additional, Bonventre, Joseph V., additional, Bowling, C. Barrett, additional, Brewster, Ursula C., additional, Briggs, Josephine P., additional, Cattran, Daniel C., additional, Chandran, Sindhu, additional, Chapman, Arlene B., additional, Coca, Steven G., additional, Conlon, Peter J., additional, Copelovitch, Lawrence A., additional, Curhan, Gary, additional, D’Agati, Vivette D., additional, Daoud, Jacques R., additional, de Zeeuw, Dick, additional, Dennen, Paula, additional, Derebail, Vimal K., additional, DuBose, Thomas D., additional, Emmett, Michael, additional, Fairhead, Todd, additional, Falk, Ronald J., additional, Feehally, John, additional, Fernández, Javier, additional, Fervenza, Fernando C., additional, Fioretto, Paola, additional, Födinger, Manuela, additional, Furth, Susan L., additional, Gehr, Todd W.B., additional, Gilbert, Scott J., additional, Gill, Jagbir S., additional, Gipson, Debbie S., additional, Goldstein-Fuchs, D. Jordi, additional, Greenberg, Arthur, additional, Gregory, Martin C., additional, Gunaratnam, Lakshman, additional, Hakim, Raymond M., additional, Hildebrandt, Friedhelm, additional, Hladunewich, Michelle A., additional, Hogan, Jonathan, additional, Hou, Susan, additional, House, Andrew A., additional, Huan, Yonghong, additional, Hutchison, Alastair J., additional, Inker, Lesley A., additional, James, Matthew T., additional, Jayne, David, additional, Jennette, J. Charles, additional, Jiménez, Wladimiro, additional, Kain, Renate, additional, Kalantar-Zadeh, Kamyar, additional, Kalb, Bobby, additional, Knoll, Greg, additional, Kriz, Wilhelm, additional, Tamura, Manjula Kurella, additional, LaPierre, Amy Frances, additional, Lambers Heerspink, Hiddo J., additional, Levey, Andrew S., additional, Lewis, Edmund J., additional, Linas, Stuart L., additional, Macedo, Etienne, additional, Madias, Nicolaos E., additional, Magee, Colm, additional, Mariani, Laura H., additional, Martin, Diego R., additional, Matzke, Gary R., additional, McQuillan, Rory F., additional, Mehrotra, Rajnish, additional, Mehta, Ankit N., additional, Mehta, Ravindra L., additional, Meyers, Catherine M., additional, Meyrier, Alain, additional, Moe, Sharon M., additional, Nast, Cynthia C., additional, Nicolle, Lindsay E., additional, Nolin, Thomas D., additional, O’Hare, Ann M., additional, O’Toole, John F., additional, Pannu, Neesh, additional, Perazella, Mark A., additional, Pusey, Charles D., additional, Quarles, L. Darryl, additional, Radhakrishnan, Jai, additional, Rastegar, Asghar, additional, Redahan, Lynn, additional, Rizk, Dana V., additional, Ronco, Claudio, additional, Rosenblum, Norman D., additional, Salama, Alan D., additional, Sanders, Paul W., additional, Sarnak, Mark J., additional, Scheinman, Steven J., additional, Schnermann, Jurgen B., additional, Semelka, Richard C., additional, Shirali, Anushree, additional, Sica, Domenic A., additional, Sunder-Plassmann, Gere, additional, Sutherland, Richard W., additional, Szerlip, Harold M., additional, Tonelli, Marcello, additional, Townsend, Raymond R., additional, Trachtman, Howard, additional, Turner, Jeffrey M., additional, Vardhan, Anand, additional, Vellanki, Kavitha, additional, Verbalis, Joseph G., additional, Vincenti, Flavio G., additional, Waikar, Sushrut S., additional, Weiner, Daniel E., additional, White, Colin T., additional, Whittier, William L., additional, Wilcox, Christopher S., additional, Wish, Jay B., additional, and Yiu, Vivian, additional

Published
2014
Full Text
View/download PDF

271. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.

Author

Heerspink, Hiddo J L, Stack, Austin G, Terkeltaub, Robert, Greene, Tom A, Inker, Lesley A, Bjursell, Magnus, Perl, Shira, Rikte, Tord, Erlandsson, Fredrik, and Perkovic, Vlado

Subjects
CHRONIC kidney failure, CHRONICALLY ill, HYPERURICEMIA, ALLOPURINOL, TYPE 2 diabetes
Abstract

Background Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% confidence interval 4–62%) among patients with Type 2 diabetes mellitus, hyperuricaemia and albuminuria. The Phase 2b, randomized, placebo-controlled Study of verinurAd and alloPurinol in Patients with cHronic kIdney disease and hyperuRicaEmia (SAPPHIRE; NCT03990363) will examine the effect of verinurad + allopurinol on albuminuria and estimated glomerular filtration rate (eGFR) slope among patients with chronic kidney disease (CKD) and hyperuricaemia. Methods Adults (≥18 years of age) with CKD, eGFR ≥25 mL/min/1.73 m2, UACR 30–5000 mg/g and sUA ≥6.0 mg/dL will be enrolled. Approximately 725 patients will be randomized 1:1:1:1:1 to 12, 7.5 or 3 mg verinurad + allopurinol, allopurinol or placebo. An 8-week dose-titration period will precede a 12-month treatment period; verinurad dose will be increased to 24 mg at Month 9 in a subset of patients in the 3 mg verinurad + allopurinol arm. The primary efficacy endpoint the is change from baseline in UACR at 6 months. Secondary efficacy endpoints include changes in UACR, eGFR and sUA from baseline at 6 and 12 months. Conclusions This study will assess the combined clinical effect of verinurad + allopurinol on kidney function in patients with CKD, hyperuricaemia and albuminuria, and whether this combination confers renoprotection beyond standard-of-care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

273. Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race.

Author

Gutiérrez, Orlando M., Sang, Yingying, Grams, Morgan E., Ballew, Shoshana H., Surapaneni, Aditya, Matsushita, Kunihiro, Go, Alan S., Shlipak, Michael G., Inker, Lesley A., Eneanya, Nwamaka D., Crews, Deidra C., Powe, Neil R., Levey, Andrew S., and Coresh, Josef

Subjects
CHRONIC kidney failure, PROTEINS, GLOMERULAR filtration rate, RESEARCH, RESEARCH methodology, RETROSPECTIVE studies, EVALUATION research, COMPARATIVE studies, RESEARCH funding, CREATININE
Abstract

Importance: At a given estimated glomerular filtration rate (eGFR), individuals who are Black have higher rates of mortality and kidney failure with replacement therapy (KFRT) compared with those who are non-Black. Whether the recently adopted eGFR equations without race preserve racial differences in risk of mortality and KFRT at a given eGFR is unknown.Objective: To assess whether eGFR equations with and without race and cystatin C document racial differences in risk of KFRT and mortality in populations including Black and non-Black participants.Design, Setting, and Participants: Retrospective individual-level data analysis of 62 011 participants from 5 general population and 3 chronic kidney disease (CKD) US-based cohorts with serum creatinine, cystatin C, and follow-up for KFRT and mortality from 1988 to 2018.Exposures: Chronic Kidney Disease Epidemiology Collaboration equation with serum creatinine (eGFRcr with and without race), cystatin C (eGFRcys without race), or both markers (eGFRcr-cys without race).Main Outcomes and Measures: The prevalence of decreased eGFR at baseline and hazard ratios of KFRT and mortality in Black vs non-Black participants were calculated, adjusted for age and sex. Analyses were performed within each cohort and with random-effect meta-analyses of the models.Results: Among 62 011 participants (20 773 Black and 41 238 non-Black; mean age, 63 years; 53% women), the prevalence ratio (95% CI; percent prevalences) of eGFR less than 60 mL/min/1.73 m2 comparing Black with non-Black participants was 0.98 (95% CI, 0.93-1.03; 11% vs 12%) for eGFRcr with race, 0.95 (95% CI, 0.91-0.98; 17% vs 18%) for eGFRcys, and 1.2 (95% CI, 1.2-1.3; 13% vs 11%) for eGFRcr-cys but was 1.8 (95% CI, 1.7-1.8; 15% vs 9%) for eGFRcr without race. During a mean follow-up of 13 years, 8% and 4% of Black and non-Black participants experienced KFRT and 34% and 39% died, respectively. Decreased eGFR was associated with significantly greater risk of both outcomes for all equations. At an eGFR of 60 mL/min/1.73 m2, the hazard ratios for KFRT comparing Black with non-Black participants were 2.8 (95% CI, 1.6-4.9) for eGFRcr with race, 3.0 (95% CI, 1.5-5.8) for eGFRcys, and 2.8 (95% CI, 1.4-5.4) for eGFRcr-cys vs 1.3 (95% CI, 0.8-2.1) for eGFRcr without race. The 5-year absolute risk differences for KFRT comparing Black with non-Black participants were 1.4% (95% CI, 0.2%-2.6%) for eGFRcr with race, 1.1% (95% CI, 0.2%-1.9%) for eGFRcys, and 1.3% (95% CI, 0%-2.6%) for eGFRcr-cys vs 0.37% (95% CI, -0.32% to 1.05%) for eGFRcr without race. Similar patterns were observed for mortality.Conclusions and Relevance: In this retrospective analysis of 8 US cohorts including Black and non-Black individuals, the eGFR equation without race that included creatinine and cystatin C, but not the eGFR equation without race that included creatinine without cystatin C, demonstrated racial differences in the risk of KFRT and mortality throughout the range of eGFR. The eGFRcr-cys equation may be preferable to the eGFRcr equation without race for assessing racial differences in the risk of KFRT and mortality associated with low eGFR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

279. Cystatin C and Muscle Mass in Patients With Heart Failure

Author

Ivey-Miranda, Juan B., primary, Inker, Lesley A., additional, Griffin, Matthew, additional, Rao, Veena, additional, Maulion, Christopher, additional, Turner, Jeffrey M., additional, Wilson, F. Perry, additional, Tang, W.H. Wilson, additional, Levey, Andrew S., additional, and Testani, Jeffrey M., additional

Published
2021
Full Text
View/download PDF

280. Effects of Bardoxolone Methyl in Alport Syndrome

Author

Warady, Bradley, primary, Pergola, Pablo E., additional, Agarwal, Rajiv, additional, Andreoli, Sharon, additional, Appel, Gerald B., additional, Bangalore, Sripal, additional, Block, Geoffrey A., additional, Chapman, Arlene B., additional, Chin, Melanie P., additional, Gibson, Keisha L., additional, Goldsberry, Angie, additional, Iijima, Kazumoto, additional, Inker, Lesley A., additional, Kashtan, Clifford E., additional, Knebelmann, Bertrand, additional, Mariani, Laura H., additional, Meyer, Colin J., additional, Nozu, Kandai, additional, O’Grady, Megan, additional, Rheault, Michelle N., additional, Silva, Arnold L., additional, Stenvinkel, Peter, additional, Torra, Roser, additional, and Chertow, Glenn M., additional

Published
2021
Full Text
View/download PDF

281. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

Author

Chertow, Glenn M., primary, Appel, Gerald B., additional, Andreoli, Sharon, additional, Bangalore, Sripal, additional, Block, Geoffrey A., additional, Chapman, Arlene B., additional, Chin, Melanie P., additional, Gibson, Keisha L., additional, Goldsberry, Angie, additional, Iijima, Kazumoto, additional, Inker, Lesley A., additional, Knebelmann, Bertrand, additional, Mariani, Laura H., additional, Meyer, Colin J., additional, Nozu, Kandai, additional, O’Grady, Megan, additional, Silva, Arnold L., additional, Stenvinkel, Peter, additional, Torra, Roser, additional, Warady, Bradley A., additional, and Pergola, Pablo E., additional

Published
2021
Full Text
View/download PDF

287. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

Author

Roth, Gregory A., primary, Mensah, George A., additional, Johnson, Catherine O., additional, Addolorato, Giovanni, additional, Ammirati, Enrico, additional, Baddour, Larry M., additional, Barengo, Noël C., additional, Beaton, Andrea Z., additional, Benjamin, Emelia J., additional, Benziger, Catherine P., additional, Bonny, Aimé, additional, Brauer, Michael, additional, Brodmann, Marianne, additional, Cahill, Thomas J., additional, Carapetis, Jonathan, additional, Catapano, Alberico L., additional, Chugh, Sumeet S., additional, Cooper, Leslie T., additional, Coresh, Josef, additional, Criqui, Michael, additional, DeCleene, Nicole, additional, Eagle, Kim A., additional, Emmons-Bell, Sophia, additional, Feigin, Valery L., additional, Fernández-Solà, Joaquim, additional, Fowkes, Gerry, additional, Gakidou, Emmanuela, additional, Grundy, Scott M., additional, He, Feng J., additional, Howard, George, additional, Hu, Frank, additional, Inker, Lesley, additional, Karthikeyan, Ganesan, additional, Kassebaum, Nicholas, additional, Koroshetz, Walter, additional, Lavie, Carl, additional, Lloyd-Jones, Donald, additional, Lu, Hong S., additional, Mirijello, Antonio, additional, Temesgen, Awoke Misganaw, additional, Mokdad, Ali, additional, Moran, Andrew E., additional, Muntner, Paul, additional, Narula, Jagat, additional, Neal, Bruce, additional, Ntsekhe, Mpiko, additional, Moraes de Oliveira, Glaucia, additional, Otto, Catherine, additional, Owolabi, Mayowa, additional, Pratt, Michael, additional, Rajagopalan, Sanjay, additional, Reitsma, Marissa, additional, Ribeiro, Antonio Luiz P., additional, Rigotti, Nancy, additional, Rodgers, Anthony, additional, Sable, Craig, additional, Shakil, Saate, additional, Sliwa-Hahnle, Karen, additional, Stark, Benjamin, additional, Sundström, Johan, additional, Timpel, Patrick, additional, Tleyjeh, Imad M., additional, Valgimigli, Marco, additional, Vos, Theo, additional, Whelton, Paul K., additional, Yacoub, Magdi, additional, Zuhlke, Liesl, additional, Murray, Christopher, additional, Fuster, Valentin, additional, Roth, Gregory A., additional, Barengo, Noel C., additional, Beaton, Andrea, additional, Bonny, Aime, additional, Carapetis, Jonathan R., additional, Chugh, Sumeet, additional, Criqui, Michael H., additional, DeCleene, Nicole K., additional, Fernández-Sola, Joaquim, additional, Fowkes, F. Gerry R., additional, Kassebaum, Nicholas J., additional, Koroshetz, Walter J., additional, Misganaw, Awoke T., additional, Mokdad, Ali H., additional, Oliveira, Gláucia M.M., additional, Otto, Catherine M., additional, Owolabi, Mayowa O., additional, Reitsma, Marissa B., additional, Rigotti, Nancy A., additional, Sable, Craig A., additional, Shakil, Saate S., additional, Sliwa, Karen, additional, Stark, Benjamin A., additional, Tleyjeh, Imad I., additional, Zuhlke, Liesl J., additional, Abbasi-Kangevari, Mohsen, additional, Abdi, Alireza, additional, Abedi, Aidin, additional, Aboyans, Victor, additional, Abrha, Woldu A., additional, Abu-Gharbieh, Eman, additional, Abushouk, Abdelrahman I., additional, Acharya, Dilaram, additional, Adair, Tim, additional, Adebayo, Oladimeji M., additional, Ademi, Zanfina, additional, Advani, Shailesh M., additional, Afshari, Khashayar, additional, Afshin, Ashkan, additional, Agarwal, Gina, additional, Agasthi, Pradyumna, additional, Ahmad, Sohail, additional, Ahmadi, Sepideh, additional, Ahmed, Muktar B., additional, Aji, Budi, additional, Akalu, Yonas, additional, Akande-Sholabi, Wuraola, additional, Aklilu, Addis, additional, Akunna, Chisom J., additional, Alahdab, Fares, additional, Al-Eyadhy, Ayman, additional, Alhabib, Khalid F., additional, Alif, Sheikh M., additional, Alipour, Vahid, additional, Aljunid, Syed M., additional, Alla, François, additional, Almasi-Hashiani, Amir, additional, Almustanyir, Sami, additional, Al-Raddadi, Rajaa M., additional, Amegah, Adeladza K., additional, Amini, Saeed, additional, Aminorroaya, Arya, additional, Amu, Hubert, additional, Amugsi, Dickson A., additional, Ancuceanu, Robert, additional, Anderlini, Deanna, additional, Andrei, Tudorel, additional, Andrei, Catalina Liliana, additional, Ansari-Moghaddam, Alireza, additional, Anteneh, Zelalem A., additional, Antonazzo, Ippazio Cosimo, additional, Antony, Benny, additional, Anwer, Razique, additional, Appiah, Lambert T., additional, Arabloo, Jalal, additional, Ärnlöv, Johan, additional, Artanti, Kurnia D., additional, Ataro, Zerihun, additional, Ausloos, Marcel, additional, Avila-Burgos, Leticia, additional, Awan, Asma T., additional, Awoke, Mamaru A., additional, Ayele, Henok T., additional, Ayza, Muluken A., additional, Azari, Samad, additional, B, Darshan B., additional, Baheiraei, Nafiseh, additional, Baig, Atif A., additional, Bakhtiari, Ahad, additional, Banach, Maciej, additional, Banik, Palash C., additional, Baptista, Emerson A., additional, Barboza, Miguel A., additional, Barua, Lingkan, additional, Basu, Sanjay, additional, Bedi, Neeraj, additional, Béjot, Yannick, additional, Bennett, Derrick A., additional, Bensenor, Isabela M., additional, Berman, Adam E., additional, Bezabih, Yihienew M., additional, Bhagavathula, Akshaya S., additional, Bhaskar, Sonu, additional, Bhattacharyya, Krittika, additional, Bijani, Ali, additional, Bikbov, Boris, additional, Birhanu, Mulugeta M., additional, Boloor, Archith, additional, Brant, Luisa C., additional, Brenner, Hermann, additional, Briko, Nikolay I., additional, Butt, Zahid A., additional, Caetano dos Santos, Florentino Luciano, additional, Cahill, Leah E., additional, Cahuana-Hurtado, Lucero, additional, Cámera, Luis A., additional, Campos-Nonato, Ismael R., additional, Cantu-Brito, Carlos, additional, Car, Josip, additional, Carrero, Juan J., additional, Carvalho, Felix, additional, Castañeda-Orjuela, Carlos A., additional, Catalá-López, Ferrán, additional, Cerin, Ester, additional, Charan, Jaykaran, additional, Chattu, Vijay Kumar, additional, Chen, Simiao, additional, Chin, Ken L., additional, Choi, Jee-Young J., additional, Chu, Dinh-Toi, additional, Chung, Sheng-Chia, additional, Cirillo, Massimo, additional, Coffey, Sean, additional, Conti, Sara, additional, Costa, Vera M., additional, Cundiff, David K., additional, Dadras, Omid, additional, Dagnew, Baye, additional, Dai, Xiaochen, additional, Damasceno, Albertino A.M., additional, Dandona, Lalit, additional, Dandona, Rakhi, additional, Davletov, Kairat, additional, De la Cruz-Góngora, Vanessa, additional, De la Hoz, Fernando P., additional, De Neve, Jan-Walter, additional, Denova-Gutiérrez, Edgar, additional, Derbew Molla, Meseret, additional, Derseh, Behailu T., additional, Desai, Rupak, additional, Deuschl, Günther, additional, Dharmaratne, Samath D., additional, Dhimal, Meghnath, additional, Dhungana, Raja Ram, additional, Dianatinasab, Mostafa, additional, Diaz, Daniel, additional, Djalalinia, Shirin, additional, Dokova, Klara, additional, Douiri, Abdel, additional, Duncan, Bruce B., additional, Duraes, Andre R., additional, Eagan, Arielle W., additional, Ebtehaj, Sanam, additional, Eftekhari, Aziz, additional, Eftekharzadeh, Sahar, additional, Ekholuenetale, Michael, additional, El Nahas, Nevine, additional, Elgendy, Islam Y., additional, Elhadi, Muhammed, additional, El-Jaafary, Shaimaa I., additional, Esteghamati, Sadaf, additional, Etisso, Atkilt E., additional, Eyawo, Oghenowede, additional, Fadhil, Ibtihal, additional, Faraon, Emerito Jose A., additional, Faris, Pawan S., additional, Farwati, Medhat, additional, Farzadfar, Farshad, additional, Fernandes, Eduarda, additional, Fernandez Prendes, Carlota, additional, Ferrara, Pietro, additional, Filip, Irina, additional, Fischer, Florian, additional, Flood, David, additional, Fukumoto, Takeshi, additional, Gad, Mohamed M., additional, Gaidhane, Shilpa, additional, Ganji, Morsaleh, additional, Garg, Jalaj, additional, Gebre, Abadi K., additional, Gebregiorgis, Birhan G., additional, Gebregzabiher, Kidane Z., additional, Gebremeskel, Gebreamlak G., additional, Getacher, Lemma, additional, Obsa, Abera Getachew, additional, Ghajar, Alireza, additional, Ghashghaee, Ahmad, additional, Ghith, Nermin, additional, Giampaoli, Simona, additional, Gilani, Syed Amir, additional, Gill, Paramjit S., additional, Gillum, Richard F., additional, Glushkova, Ekaterina V., additional, Gnedovskaya, Elena V., additional, Golechha, Mahaveer, additional, Gonfa, Kebebe B., additional, Goudarzian, Amir Hossein, additional, Goulart, Alessandra C., additional, Guadamuz, Jenny S., additional, Guha, Avirup, additional, Guo, Yuming, additional, Gupta, Rajeev, additional, Hachinski, Vladimir, additional, Hafezi-Nejad, Nima, additional, Haile, Teklehaimanot G., additional, Hamadeh, Randah R., additional, Hamidi, Samer, additional, Hankey, Graeme J., additional, Hargono, Arief, additional, Hartono, Risky K., additional, Hashemian, Maryam, additional, Hashi, Abdiwahab, additional, Hassan, Shoaib, additional, Hassen, Hamid Y., additional, Havmoeller, Rasmus J., additional, Hay, Simon I., additional, Hayat, Khezar, additional, Heidari, Golnaz, additional, Herteliu, Claudiu, additional, Holla, Ramesh, additional, Hosseini, Mostafa, additional, Hosseinzadeh, Mehdi, additional, Hostiuc, Mihaela, additional, Hostiuc, Sorin, additional, Househ, Mowafa, additional, Huang, Junjie, additional, Humayun, Ayesha, additional, Iavicoli, Ivo, additional, Ibeneme, Charles U., additional, Ibitoye, Segun E., additional, Ilesanmi, Olayinka S., additional, Ilic, Irena M., additional, Ilic, Milena D., additional, Iqbal, Usman, additional, Irvani, Seyed Sina N., additional, Islam, Sheikh Mohammed Shariful, additional, Islam, Rakibul M., additional, Iso, Hiroyasu, additional, Iwagami, Masao, additional, Jain, Vardhmaan, additional, Javaheri, Tahereh, additional, Jayapal, Sathish Kumar, additional, Jayaram, Shubha, additional, Jayawardena, Ranil, additional, Jeemon, Panniyammakal, additional, Jha, Ravi P., additional, Jonas, Jost B., additional, Jonnagaddala, Jitendra, additional, Joukar, Farahnaz, additional, Jozwiak, Jacek J., additional, Jürisson, Mikk, additional, Kabir, Ali, additional, Kahlon, Tanvir, additional, Kalani, Rizwan, additional, Kalhor, Rohollah, additional, Kamath, Ashwin, additional, Kamel, Ibrahim, additional, Kandel, Himal, additional, Kandel, Amit, additional, Karch, André, additional, Kasa, Ayele Semachew, additional, Katoto, Patrick D.M.C., additional, Kayode, Gbenga A., additional, Khader, Yousef S., additional, Khammarnia, Mohammad, additional, Khan, Muhammad S., additional, Khan, Md Nuruzzaman, additional, Khan, Maseer, additional, Khan, Ejaz A., additional, Khatab, Khaled, additional, Kibria, Gulam M.A., additional, Kim, Yun Jin, additional, Kim, Gyu Ri, additional, Kimokoti, Ruth W., additional, Kisa, Sezer, additional, Kisa, Adnan, additional, Kivimäki, Mika, additional, Kolte, Dhaval, additional, Koolivand, Ali, additional, Korshunov, Vladimir A., additional, Koulmane Laxminarayana, Sindhura Lakshmi, additional, Koyanagi, Ai, additional, Krishan, Kewal, additional, Krishnamoorthy, Vijay, additional, Kuate Defo, Barthelemy, additional, Kucuk Bicer, Burcu, additional, Kulkarni, Vaman, additional, Kumar, G. Anil, additional, Kumar, Nithin, additional, Kurmi, Om P., additional, Kusuma, Dian, additional, Kwan, Gene F., additional, La Vecchia, Carlo, additional, Lacey, Ben, additional, Lallukka, Tea, additional, Lan, Qing, additional, Lasrado, Savita, additional, Lassi, Zohra S., additional, Lauriola, Paolo, additional, Lawrence, Wayne R., additional, Laxmaiah, Avula, additional, LeGrand, Kate E., additional, Li, Ming-Chieh, additional, Li, Bingyu, additional, Li, Shanshan, additional, Lim, Stephen S., additional, Lim, Lee-Ling, additional, Lin, Hualiang, additional, Lin, Ziqiang, additional, Lin, Ro-Ting, additional, Liu, Xuefeng, additional, Lopez, Alan D., additional, Lorkowski, Stefan, additional, Lotufo, Paulo A., additional, Lugo, Alessandra, additional, M, Nirmal K., additional, Madotto, Fabiana, additional, Mahmoudi, Morteza, additional, Majeed, Azeem, additional, Malekzadeh, Reza, additional, Malik, Ahmad A., additional, Mamun, Abdullah A., additional, Manafi, Navid, additional, Mansournia, Mohammad Ali, additional, Mantovani, Lorenzo G., additional, Martini, Santi, additional, Mathur, Manu R., additional, Mazzaglia, Giampiero, additional, Mehata, Suresh, additional, Mehndiratta, Man Mohan, additional, Meier, Toni, additional, Menezes, Ritesh G., additional, Meretoja, Atte, additional, Mestrovic, Tomislav, additional, Miazgowski, Bartosz, additional, Miazgowski, Tomasz, additional, Michalek, Irmina Maria, additional, Miller, Ted R., additional, Mirrakhimov, Erkin M., additional, Mirzaei, Hamed, additional, Moazen, Babak, additional, Moghadaszadeh, Masoud, additional, Mohammad, Yousef, additional, Mohammad, Dara K., additional, Mohammed, Shafiu, additional, Mohammed, Mohammed A., additional, Mokhayeri, Yaser, additional, Molokhia, Mariam, additional, Montasir, Ahmed A., additional, Moradi, Ghobad, additional, Moradzadeh, Rahmatollah, additional, Moraga, Paula, additional, Morawska, Lidia, additional, Moreno Velásquez, Ilais, additional, Morze, Jakub, additional, Mubarik, Sumaira, additional, Muruet, Walter, additional, Musa, Kamarul Imran, additional, Nagarajan, Ahamarshan J., additional, Nalini, Mahdi, additional, Nangia, Vinay, additional, Naqvi, Atta Abbas, additional, Narasimha Swamy, Sreenivas, additional, Nascimento, Bruno R., additional, Nayak, Vinod C., additional, Nazari, Javad, additional, Nazarzadeh, Milad, additional, Negoi, Ruxandra I., additional, Neupane Kandel, Sandhya, additional, Nguyen, Huong L.T., additional, Nixon, Molly R., additional, Norrving, Bo, additional, Noubiap, Jean Jacques, additional, Nouthe, Brice E., additional, Nowak, Christoph, additional, Odukoya, Oluwakemi O., additional, Ogbo, Felix A., additional, Olagunju, Andrew T., additional, Orru, Hans, additional, Ortiz, Alberto, additional, Ostroff, Samuel M., additional, Padubidri, Jagadish Rao, additional, Palladino, Raffaele, additional, Pana, Adrian, additional, Panda-Jonas, Songhomitra, additional, Parekh, Utsav, additional, Park, Eun-Cheol, additional, Parvizi, Mojtaba, additional, Pashazadeh Kan, Fatemeh, additional, Patel, Urvish K., additional, Pathak, Mona, additional, Paudel, Rajan, additional, Pepito, Veincent Christian F., additional, Perianayagam, Arokiasamy, additional, Perico, Norberto, additional, Pham, Hai Q., additional, Pilgrim, Thomas, additional, Piradov, Michael A., additional, Pishgar, Farhad, additional, Podder, Vivek, additional, Polibin, Roman V., additional, Pourshams, Akram, additional, Pribadi, Dimas R.A., additional, Rabiee, Navid, additional, Rabiee, Mohammad, additional, Radfar, Amir, additional, Rafiei, Alireza, additional, Rahim, Fakher, additional, Rahimi-Movaghar, Vafa, additional, Ur Rahman, Mohammad Hifz, additional, Rahman, Muhammad Aziz, additional, Rahmani, Amir Masoud, additional, Rakovac, Ivo, additional, Ram, Pradhum, additional, Ramalingam, Sudha, additional, Rana, Juwel, additional, Ranasinghe, Priyanga, additional, Rao, Sowmya J., additional, Rathi, Priya, additional, Rawal, Lal, additional, Rawasia, Wasiq F., additional, Rawassizadeh, Reza, additional, Remuzzi, Giuseppe, additional, Renzaho, Andre M.N., additional, Rezapour, Aziz, additional, Riahi, Seyed Mohammad, additional, Roberts-Thomson, Ross L., additional, Roever, Leonardo, additional, Rohloff, Peter, additional, Romoli, Michele, additional, Roshandel, Gholamreza, additional, Rwegerera, Godfrey M., additional, Saadatagah, Seyedmohammad, additional, Saber-Ayad, Maha M., additional, Sabour, Siamak, additional, Sacco, Simona, additional, Sadeghi, Masoumeh, additional, Saeedi Moghaddam, Sahar, additional, Safari, Saeed, additional, Sahebkar, Amirhossein, additional, Salehi, Sana, additional, Salimzadeh, Hamideh, additional, Samaei, Mehrnoosh, additional, Samy, Abdallah M., additional, Santos, Itamar S., additional, Santric-Milicevic, Milena M., additional, Sarrafzadegan, Nizal, additional, Sarveazad, Arash, additional, Sathish, Thirunavukkarasu, additional, Sawhney, Monika, additional, Saylan, Mete, additional, Schmidt, Maria I., additional, Schutte, Aletta E., additional, Senthilkumaran, Subramanian, additional, Sepanlou, Sadaf G., additional, Sha, Feng, additional, Shahabi, Saeed, additional, Shahid, Izza, additional, Shaikh, Masood A., additional, Shamali, Mahdi, additional, Shamsizadeh, Morteza, additional, Shawon, Md Shajedur Rahman, additional, Sheikh, Aziz, additional, Shigematsu, Mika, additional, Shin, Min-Jeong, additional, Shin, Jae Il, additional, Shiri, Rahman, additional, Shiue, Ivy, additional, Shuval, Kerem, additional, Siabani, Soraya, additional, Siddiqi, Tariq J., additional, Silva, Diego A.S., additional, Singh, Jasvinder A., additional, Mtech, Ambrish Singh, additional, Skryabin, Valentin Y., additional, Skryabina, Anna A., additional, Soheili, Amin, additional, Spurlock, Emma E., additional, Stockfelt, Leo, additional, Stortecky, Stefan, additional, Stranges, Saverio, additional, Suliankatchi Abdulkader, Rizwan, additional, Tadbiri, Hooman, additional, Tadesse, Eyayou G., additional, Tadesse, Degena B., additional, Tajdini, Masih, additional, Tariqujjaman, Md, additional, Teklehaimanot, Berhane F., additional, Temsah, Mohamad-Hani, additional, Tesema, Ayenew K., additional, Thakur, Bhaskar, additional, Thankappan, Kavumpurathu R., additional, Thapar, Rekha, additional, Thrift, Amanda G., additional, Timalsina, Binod, additional, Tonelli, Marcello, additional, Touvier, Mathilde, additional, Tovani-Palone, Marcos R., additional, Tripathi, Avnish, additional, Tripathy, Jaya P., additional, Truelsen, Thomas C., additional, Tsegay, Guesh M., additional, Tsegaye, Gebiyaw W., additional, Tsilimparis, Nikolaos, additional, Tusa, Biruk S., additional, Tyrovolas, Stefanos, additional, Umapathi, Krishna Kishore, additional, Unim, Brigid, additional, Unnikrishnan, Bhaskaran, additional, Usman, Muhammad S., additional, Vaduganathan, Muthiah, additional, Valdez, Pascual R., additional, Vasankari, Tommi J., additional, Velazquez, Diana Z., additional, Venketasubramanian, Narayanaswamy, additional, Vu, Giang T., additional, Vujcic, Isidora S., additional, Waheed, Yasir, additional, Wang, Yanzhong, additional, Wang, Fang, additional, Wei, Jingkai, additional, Weintraub, Robert G., additional, Weldemariam, Abrha H., additional, Westerman, Ronny, additional, Winkler, Andrea S., additional, Wiysonge, Charles S., additional, Wolfe, Charles D.A., additional, Wubishet, Befikadu Legesse, additional, Xu, Gelin, additional, Yadollahpour, Ali, additional, Yamagishi, Kazumasa, additional, Yan, Lijing L., additional, Yandrapalli, Srikanth, additional, Yano, Yuichiro, additional, Yatsuya, Hiroshi, additional, Yeheyis, Tomas Y., additional, Yeshaw, Yigizie, additional, Yilgwan, Christopher S., additional, Yonemoto, Naohiro, additional, Yu, Chuanhua, additional, Yusefzadeh, Hasan, additional, Zachariah, Geevar, additional, Zaman, Sojib Bin, additional, Zaman, Muhammed S., additional, Zamanian, Maryam, additional, Zand, Ramin, additional, Zandifar, Alireza, additional, Zarghi, Afshin, additional, Zastrozhin, Mikhail S., additional, Zastrozhina, Anasthasia, additional, Zhang, Zhi-Jiang, additional, Zhang, Yunquan, additional, Zhang, Wangjian, additional, Zhong, Chenwen, additional, Zou, Zhiyong, additional, Zuniga, Yves Miel H., additional, and Murray, Christopher J.L., additional

Published
2020
Full Text
View/download PDF

288. Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference

Author

Edmonston, Daniel L., primary, Roe, Matthew T., additional, Block, Geoffrey, additional, Conway, Paul T., additional, Dember, Laura M., additional, DiBattiste, Peter M., additional, Greene, Tom, additional, Hariri, Ali, additional, Inker, Lesley A., additional, Isakova, Tamara, additional, Montez-Rath, Maria E., additional, Nkulikiyinka, Richard, additional, Polidori, David, additional, Roessig, Lothar, additional, Tangri, Navdeep, additional, Wyatt, Christina, additional, Chertow, Glenn M., additional, and Wolf, Myles, additional

Published
2020
Full Text
View/download PDF

292. International consensus definitions of clinical trial outcomes for kidney failure: 2020

Author

Levin, Adeera, primary, Agarwal, Rajiv, additional, Herrington, William G., additional, Heerspink, Hiddo L., additional, Mann, Johannes F.E., additional, Shahinfar, Shahnaz, additional, Tuttle, Katherine R., additional, Donner, Jo-Ann, additional, Jha, Vivekanand, additional, Nangaku, Masaomi, additional, de Zeeuw, Dick, additional, Jardine, Meg J., additional, Mahaffey, Kenneth W., additional, Thompson, Aliza M., additional, Beaucage, Mary, additional, Chong, Kate, additional, Roberts, Glenda V., additional, Sunwold, Duane, additional, Vorster, Hans, additional, Warren, Madeleine, additional, Damster, Sandrine, additional, Malik, Charu, additional, Perkovic, Vlado, additional, Anand, Shuchi, additional, Argent, Nicholas, additional, Babak, Elena, additional, Banerjee, Debasish, additional, Barratt, Jonathan, additional, Bello, Aminu K., additional, Bernardo, Angelito A., additional, Blais, Jaime, additional, Canovatchel, William, additional, Caskey, Fergus J., additional, Coresh, Josef, additional, de Boer, Ian H., additional, Eckardt, Kai-Uwe, additional, Evans, Rhys DR., additional, Feldman, Harold I., additional, Fogo, Agnes B., additional, Gudmundsdottir, Hrefna, additional, Hamano, Takayuki, additional, Harris, David C.H., additional, Hauske, Sibylle J., additional, Haynes, Richard, additional, Herzog, Charles A., additional, Hiemstra, Thomas, additional, Idorn, Thomas, additional, Inker, Lesley, additional, Ishida, Julie H., additional, Johnson, David W., additional, Jones-Burton, Charlotte, additional, Joseph, Amer, additional, Koitka-Weber, Audrey, additional, Kretzler, Matthias, additional, Lawatscheck, Robert, additional, Liew, Adrian, additional, Moist, Louise, additional, Naicker, Saraladevi, additional, Nakashima, Reiko, additional, Patel, Uptal, additional, Filho, Roberto Pecoits, additional, Rose, Jennifer B., additional, Rosenberg, Noah L., additional, Sinsakul, Marvin, additional, Smoyer, William E., additional, Sola, Laura, additional, Sood, Amy R., additional, Stengel, Benedicte, additional, Taal, Maarten W., additional, Tanaka, Mototsugu, additional, Tonelli, Marcello, additional, Tong, Allison, additional, Toto, Robert, additional, Trask, Michele, additional, Ulasi, Ifeoma I., additional, Wanner, Christoph, additional, Wheeler, David C., additional, Wolthers, Benjamin O., additional, Wright, Harold M., additional, Yamada, Yoshihisa, additional, and Zakharova, Elena, additional

Published
2020
Full Text
View/download PDF

293. Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

Author

Waijer, Simke W., primary, Xie, Di, additional, Inzucchi, Silvio E., additional, Zinman, Bernard, additional, Koitka‐Weber, Audrey, additional, Mattheus, Michaela, additional, von Eynatten, Maximillian, additional, Inker, Lesley A., additional, Wanner, Christoph, additional, and Heerspink, Hiddo J. L., additional

Published
2020
Full Text
View/download PDF

296. GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts

Author

Eriksen, Bjørn O., primary, Palsson, Runolfur, additional, Ebert, Natalie, additional, Melsom, Toralf, additional, van der Giet, Markus, additional, Gudnason, Vilmundur, additional, Indridason, Olafur S., additional, Inker, Lesley A., additional, Jenssen, Trond G., additional, Levey, Andrew S., additional, Solbu, Marit D., additional, Tighiouart, Hocine, additional, and Schaeffner, Elke, additional

Published
2020
Full Text
View/download PDF

297. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Author

Levey, Andrew S., primary, Eckardt, Kai-Uwe, additional, Dorman, Nijsje M., additional, Christiansen, Stacy L., additional, Hoorn, Ewout J., additional, Ingelfinger, Julie R., additional, Inker, Lesley A., additional, Levin, Adeera, additional, Mehrotra, Rajnish, additional, Palevsky, Paul M., additional, Perazella, Mark A., additional, Tong, Allison, additional, Allison, Susan J., additional, Bockenhauer, Detlef, additional, Briggs, Josephine P., additional, Bromberg, Jonathan S., additional, Davenport, Andrew, additional, Feldman, Harold I., additional, Fouque, Denis, additional, Gansevoort, Ron T., additional, Gill, John S., additional, Greene, Eddie L., additional, Hemmelgarn, Brenda R., additional, Kretzler, Matthias, additional, Lambie, Mark, additional, Lane, Pascale H., additional, Laycock, Joseph, additional, Leventhal, Shari E., additional, Mittelman, Michael, additional, Morrissey, Patricia, additional, Ostermann, Marlies, additional, Rees, Lesley, additional, Ronco, Pierre, additional, Schaefer, Franz, additional, St. Clair Russell, Jennifer, additional, Vinck, Caroline, additional, Walsh, Stephen B., additional, Weiner, Daniel E., additional, Cheung, Michael, additional, Jadoul, Michel, additional, and Winkelmayer, Wolfgang C., additional

Published
2020
Full Text
View/download PDF

299. Bisphosphonate utilization across the spectrum of eGFR

Author

Titan, Silvia M., primary, Laureati, Paola, additional, Sang, Yingying, additional, Chang, Alex R., additional, Evans, Marie, additional, Trevisan, Marco, additional, Levey, Andrew S., additional, Grams, Morgan E., additional, Inker, Lesley A., additional, and Carrero, Juan-Jesus, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results